The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities – the United States Food and Drug Administration (FDA) and the E...
Main Author: | |
---|---|
Corporate Author: | |
Format: | Electronic eBook |
Language: | English |
Published: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
Edition: | 2nd ed. 2013. |
Subjects: | |
Online Access: | Full Text via HEAL-Link |
Table of Contents:
- Complexity of Biologica CMC Regulation
- Biologics are Not Chemical Drugs
- An Effective CMC Strategy is Possible
- Challenge of Adventitious Agent Control
- Source Materials for Biologics
- Manufacture of the Biologic API
- The Biologic Final Product Process
- Complex Process-Related Impurities
- Molecular Structural Analysis
- Functional Activity (Potency)
- Setting Specifications and Expiry Dates
- Demonstrating Product Comparability
- CMC-Focused Regulatory Meetings
- References.